| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 0.56 [0.31, 1.02] | | < 1 | | 0% | 5 studies (5/-) | 97.0 % | some concern | not evaluable | moderate | crucial | - |
| deaths | 0.79 [0.59, 1.07] | | < 1 | | 0% | 18 studies (18/-) | 93.8 % | some concern | critical | moderate | crucial | - |
| deaths (time to event analysis only) | 0.64 [0.28, 1.48] | | < 1 | | 0% | 3 studies (3/-) | 85.1 % | some concern | not evaluable | moderate | crucial | - |
| clinical deterioration | 0.98 [0.68, 1.41] | | < 1 | | 37% | 7 studies (7/-) | 54.8 % | some concern | not evaluable | moderate | important | - |
| clinical improvement | 1.33 [1.00, 1.76] | | > 1 | | 73% | 11 studies (11/-) | 97.7 % | some concern | low | moderate | important | - |
| clinical improvement (14-day) | 1.24 [1.03, 1.48] | | > 1 | | 25% | 8 studies (8/-) | 98.9 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.47 [1.06, 2.04] | | > 1 | | 59% | 4 studies (4/-) | 99.0 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (7-day) | 1.28 [1.01, 1.62] | | > 1 | | 69% | 8 studies (8/-) | 97.8 % | some concern | serious | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.22 [1.01, 1.49] | | > 1 | | 73% | 10 studies (10/-) | 97.8 % | some concern | critical | moderate | important | - |
| hospital discharge | 1.20 [0.81, 1.77] | | > 1 | | 59% | 4 studies (4/-) | 81.7 % | some concern | not evaluable | moderate | important | - |
| mechanical ventilation | 0.78 [0.41, 1.49] | | < 1 | | 51% | 9 studies (9/-) | 77.2 % | some concern | serious | moderate | important | - |
| mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
| radiologic improvement (14-day) | 1.17 [0.42, 3.26] | | > 1 | | 16% | 3 studies (3/-) | 62.1 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.08 [0.01, 0.44] | | > 1 | | 0% | 3 studies (3/-) | 0.2 % | some concern | not evaluable | moderate | important | - |
| viral clearance | 1.69 [1.10, 2.57] | | > 1 | | 76% | 10 studies (10/-) | 99.2 % | some concern | low | moderate | important | - |
| viral clearance (time to event analysis only) | 1.69 [1.02, 2.78] | | > 1 | | 72% | 3 studies (3/-) | 97.9 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 0.99 [0.93, 1.06] | | > 1 | | 0% | 6 studies (6/-) | 43.0 % | some concern | serious | moderate | important | - |
| viral clearance by day 7 | 1.00 [0.80, 1.25] | | > 1 | | 43% | 9 studies (9/-) | 49.5 % | some concern | not evaluable | moderate | important | - |
| ICU admission | 1.17 [0.83, 1.65] | | < 1 | | 0% | 5 studies (5/-) | 17.9 % | some concern | serious | moderate | non important | - |
| recovery | 1.03 [0.83, 1.28] | | > 1 | | 66% | 3 studies (3/-) | 60.0 % | some concern | not evaluable | moderate | non important | - |
| severe COVID-19 occurrence | 0.30 [0.07, 1.27] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| serious adverse events | 0.75 [0.47, 1.20] | | < 1 | | 0% | 12 studies (12/-) | 88.5 % | some concern | critical | moderate | important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 2.05 [1.36, 3.10] | | < 1 | | 76% | 13 studies (13/-) | 0.0 % | some concern | low | moderate | non important | - |
| arrhythmia | 2.24 [0.23, 21.69] | | < 1 | | 0% | 1 study (1/-) | 24.5 % | NA | not evaluable | | non important | - |
| elevated liver enzymes | 3.48 [1.40, 8.64] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| long QT | 9.79 [1.27, 75.50] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| renal impairment | 1.35 [0.47, 3.86] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| serious adverse events (SAE), any | 0.50 [0.32, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |
